Overview
| 别名 | Acyl-coenzyme A synthetase ACSM5; mitochondrial; Acyl-CoA synthetase medium-chain family member 5 |
| 基因名 | ACSM5 |
| UniProt ID | Q6NUN0 |
| 反应种属 | Human |
| 应用 | IHC-P |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG1 |
| 克隆号 | 6P9-P3-N2 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 64 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | IHC-1:100-1:200 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | Acyl-CoA synthetase medium chain family member 5 (ACSM5) is a mitochondrial protein that catalyzes the activation of fatty acids by CoA to produce acyl-CoA, representing the initial step in fatty acid metabolism. It exhibits fatty acid ligase and fatty-acyl-CoA synthase activities, contributing to acyl-CoA metabolic processes and arachidonate biosynthesis. ACSM5 is primarily expressed in the cytoplasm of liver and kidney tissues and shares functional similarities with its paralog, ACSM4. Clinically, ACSM5 is associated with X-linked epilepsy featuring variable learning disabilities and Abdominal Obesity-Metabolic Syndrome 1. These associations suggest that ACSM5 dysfunction leads to impaired fatty acid metabolism, potentially contributing to neurological complications and systemic metabolic dysregulation. |
检测原理